Stable Gastric Pentadecapeptide BPC 157—Possible Novel Therapy of Glaucoma
/PMC/2026
Why It Matters
This paper caught my attention because BPC-157 keeps popping up in longevity circles, but almost always with sketchy evidence. Here we have actual mechanistic data in a disease model—glaucoma—where the peptide appears to protect eye tissue from pressure damage. That said, this is purely rat data. No human trials exist for BPC-157 in glaucoma, and the peptide isn't FDA-approved for anything. Interesting biology, but a very long way from something you should consider using.
Key Findings
- BPC-157 administration reduced intraocular pressure in rats with experimentally induced glaucoma compared to untreated controls
- The peptide preserved retinal ganglion cells and nerve fiber layer thickness, which typically degenerate in glaucoma
- BPC-157 appeared to modulate nitric oxide pathways and reduce oxidative stress in eye tissues—potential mechanisms for the protective effects
- Effects were seen with multiple administration routes (topical, intraperitoneal, and per-oral), suggesting systemic bioavailability
- Study was preclinical only using rat models—no human safety or efficacy data for eye conditions
Read the Paper↗PMC10385428